Researchers at Mass General Brigham Heart and Vascular Institute, in collaboration with partners, have developed and validated a new genetic risk test capable of estimating inherited risk for eight common cardiovascular conditions. The study, published in the Journal of the American College of Cardiology, demonstrates that individuals with high genetic risk scores face significantly greater odds of developing these diseases compared to those with average risk. This tool, currently available through the Mass General Brigham Laboratory for Molecular Medicine and Broad Clinical Labs, aims to provide a more comprehensive approach to disease prevention. Co-senior author Pradeep Natarajan, MD, noted that interpreting DNA risk remains novel for both the public and clinicians. Consequently, the team prioritized creating a clear, patient-friendly report that simplifies complex genetic data. While cardiovascular disease remains the leading cause of death worldwide, traditional risk assessments based on age, sex, blood pressure, and cholesterol often overlook individuals with significant inherited risks. To address this gap, the researchers created an integrated polygenic risk score. This single test combines data from numerous genetic variants to evaluate risk for coronary artery disease, atrial fibrillation, type 2 diabetes, venous thromboembolism, thoracic aortic aneurysm, extreme hypertension, severe hypercholesterolemia, and elevated lipoprotein(a). The model utilized previously published genetic risk models from the Polygenic Score Catalog and combined them into robust results. Training relied on genetic and health data from 245,000 participants in the National Institutes of Health's All of Us Research Program, with validation performed on 53,000 patients from the Mass General Brigham Biobank. The results were striking: individuals in the top 10% for genetic risk were 3.7 times more likely to develop coronary artery disease than those at average risk. Similarly, those in the highest risk group for type 2 diabetes were 3.1 times more likely to develop the condition. The resulting report provides a simple classification of risk as high, average, or low for each condition, accompanied by easy-to-interpret graphs comparing the patient to the general population. These findings are designed to integrate directly into electronic health records and patient portals to facilitate clinical decision-making. Co-senior author Aniruddh Patel, MD, emphasized that many patients at increased genetic risk for serious heart conditions appear low risk based on traditional metrics. The goal is to provide actionable, understandable information to clinicians and patients. The researchers acknowledge that further studies are needed to optimize the use of this information in clinical settings and to ensure accuracy across diverse populations. Currently, a significant portion of the reference data is derived from populations of primarily European ancestry. Despite these limitations, the team plans to continuously refine the tool as new genetic evidence emerges, ensuring it remains a vital resource for preventing cardiovascular disease.